Key result
A review of antithrombotic treatment trials in atrial fibrillation discusses risk stratification and presents recommendations for anticoagulation to prevent stroke.
Why the study?
What are the recommendations for antithrombotic treatment and risk stratification in patients with atrial fibrillation?
What are the recommendations for antithrombotic treatment and risk stratification in patients with atrial fibrillation?
This review discusses evidence from antithrombotic treatment trials, risk stratification, and recommendations for anticoagulation in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports anticoagulation guidance in AF; leaves open validation with contemporary risk tools.
Atrial fibrillation (AF) can significantly increase morbidity and mortality. It is gaining in clinical and economic importance, being the most commonly encountered tachyarrhythmia in clinical practice. Stroke is the most serious complication. Evidence from AF antithrombotic treatment trials is reviewed, risk stratification of patients with AF is discussed, and recommendations for anticoagulation are presented.
No takes yet. Share an insight, caveat, or question.
Lip et al. (2005) conducted a review in Atrial fibrillation. Antithrombotic treatment was evaluated. A review of antithrombotic treatment trials in atrial fibrillation discusses risk stratification and presents recommendations for anticoagulation to prevent stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: